These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 1837965

  • 1. [Side effects of oral contraceptives in the first treatment cycle].
    Feichtinger W, Babor P, Herczeg KM, Heyda M, Hoffmann R, Plöckinger B, Steinhauser B.
    Wien Med Wochenschr; 1991; 141(18-19):412-5. PubMed ID: 1837965
    [Abstract] [Full Text] [Related]

  • 2. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P, Loner U, Kapiotis S, Handler S, Schneider B, Huber J, Speiser W.
    Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
    [Abstract] [Full Text] [Related]

  • 3. Comparative metabolic effects of oral contraceptive preparations containing different progestagens. Effects of desogestrel + ethinylestradiol on the haemostatic balance.
    Rákóczi I, Gerö G, Demeter J, Gáti I.
    Arzneimittelforschung; 1985 Nov; 35(3):630-3. PubMed ID: 3158320
    [Abstract] [Full Text] [Related]

  • 4. Clinical study of a monophasic pill containing 20 microg ethinylestradiol and 150 microg desogestrel in Thai women.
    Jaisamrarn U, Reinprayoon D, Virutamasen P.
    J Med Assoc Thai; 2001 Jun; 84 Suppl 1():S377-83. PubMed ID: 11529361
    [Abstract] [Full Text] [Related]

  • 5. A large observational clinical evaluation of a desogestrel-containing combiphasic oral contraceptive in Germany.
    Vree ML, Schmidt J.
    Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):108-14. PubMed ID: 11518448
    [Abstract] [Full Text] [Related]

  • 6. [Acceptability and secondary effects of a new oral contraceptive containing ethinylestradiol and gestodene].
    Cremer P, Vekemans M.
    Rev Med Brux; 1987 Nov; 8(9):440-6. PubMed ID: 3423522
    [No Abstract] [Full Text] [Related]

  • 7. Clinical experience of a combined oral contraceptive with very low dose ethinyl estradiol.
    Akerlund M.
    Acta Obstet Gynecol Scand Suppl; 1997 Nov; 164():63-5. PubMed ID: 9225641
    [Abstract] [Full Text] [Related]

  • 8. European Society of Contraception oral contraceptives survey update: birth control methods in "Europe of the 12".
    Serfaty D, Wildemeersch D, Verougstraete A, Creatsas G.
    Int J Fertil Menopausal Stud; 1995 Nov; 40 Suppl 2():73-9. PubMed ID: 8574253
    [Abstract] [Full Text] [Related]

  • 9. [Effect of hormonal contraceptives containing 0.05 mg ethinyl estradiol and 0.125 mg desogestrel in normophasic regimen (Oviol)].
    Weijers MJ.
    Fortschr Med; 1982 Apr 29; 100(16):764-7. PubMed ID: 6211403
    [Abstract] [Full Text] [Related]

  • 10. Clinical studies with a new, low-dose oral contraceptive combination, containing 0.150 mg desogestrel and 0.020 mg ethinylestradiol.
    Acta Obstet Gynecol Scand Suppl; 1987 Apr 29; 144():1-44. PubMed ID: 2964165
    [No Abstract] [Full Text] [Related]

  • 11. A new ultra-low-dose combination oral contraceptive.
    Woutersz TB.
    J Reprod Med; 1983 Jan 29; 28(1 Suppl):81-4. PubMed ID: 6403705
    [Abstract] [Full Text] [Related]

  • 12. Multicentre study with a new biphasic oral contraceptive containing ethinylestradiol and desogestrel. Report on efficacy, cycle control and adverse experiences with special emphasis on blood pressure and weight.
    Dieben TO, van Beek A, Coelingh Bennink HJ.
    Arzneimittelforschung; 1991 Sep 29; 41(9):996-8. PubMed ID: 1839126
    [Abstract] [Full Text] [Related]

  • 13. Clinical trial of an oral contraceptive containing desogestrel and ethinyl estradiol.
    Weijers MJ.
    Clin Ther; 1982 Sep 29; 4(5):359-66. PubMed ID: 6461412
    [Abstract] [Full Text] [Related]

  • 14. [Our experience with the use of the contraceptive preparations Femovan and Triquilar from the Schering firm].
    Milchev N, Terzhumanov R, Grozdanov G, Krumov G.
    Akush Ginekol (Sofiia); 1992 Sep 29; 31(2):42-3. PubMed ID: 1342561
    [No Abstract] [Full Text] [Related]

  • 15. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation.
    Kemmeren JM, Algra A, Meijers JC, Bouma BN, Grobbee DE.
    Thromb Haemost; 2002 Feb 29; 87(2):199-205. PubMed ID: 11859850
    [Abstract] [Full Text] [Related]

  • 16. [Clinical study of a low-dose contraceptive--Femodene].
    Rachev E, Damianov L, Dukovski A, Katsarova M.
    Akush Ginekol (Sofiia); 1995 Feb 29; 34(3):71-3. PubMed ID: 8787249
    [Abstract] [Full Text] [Related]

  • 17. Effects of a monophasic pill containing 20 microg ethinylestradiol and 150 microg desogestrel on lipid metabolism in Thai women.
    Jaisamrarn U, Taneepanichskul S, Wongwathanavikromn R, Reinprayoon D.
    J Med Assoc Thai; 2002 Jun 29; 85 Suppl 1():S429-34. PubMed ID: 12188447
    [Abstract] [Full Text] [Related]

  • 18. [The efficacy of gestoden (delta 15-d-norgestrel) as ovulation inhibitor (author's transl)].
    Schneider WH, Schmid R, Spona J.
    Wien Klin Wochenschr; 1981 Oct 16; 93(19):601-4. PubMed ID: 6798765
    [Abstract] [Full Text] [Related]

  • 19. [Clinical evaluation of desogestrel, the first new-generation progestagen, practil 21, on 13,290 women and 74,967 cycles].
    Bilotta P, Favilli S.
    Minerva Ginecol; 1987 Dec 16; 39(12):855-69. PubMed ID: 3329705
    [No Abstract] [Full Text] [Related]

  • 20. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel.
    Teichmann A.
    Int J Fertil Menopausal Stud; 1995 Dec 16; 40 Suppl 2():98-104. PubMed ID: 8574257
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.